Article Versions Notes

Tas ML, Dootjes LW, Fiocco M, de Krijger RR, Dierselhuis MP, van Eijkelenburg NKA, van Grotel M, Kraal KCJM, Peek AML, Tytgat GAM, et al. Anti-GD2 Based Immunotherapy Prevents Late Events in High-Risk Neuroblastoma Patients over 18 Months at Diagnosis. Cancers. 2021; 13(19):4941. https://doi.org/10.3390/cancers13194941

Tas, Michelle L., Lisa W. Dootjes, Marta Fiocco, Ronald R. de Krijger, Miranda P. Dierselhuis, Natasha K. A. van Eijkelenburg, Martine van Grotel, Kathelijne C. J. M. Kraal, Annemarie M. L. Peek, Godelieve A. M. Tytgat, and et al. 2021. "Anti-GD2 Based Immunotherapy Prevents Late Events in High-Risk Neuroblastoma Patients over 18 Months at Diagnosis" Cancers 13, no. 19: 4941. https://doi.org/10.3390/cancers13194941

Tas, M. L., Dootjes, L. W., Fiocco, M., de Krijger, R. R., Dierselhuis, M. P., van Eijkelenburg, N. K. A., van Grotel, M., Kraal, K. C. J. M., Peek, A. M. L., Tytgat, G. A. M., & van Noesel, M. M. (2021). Anti-GD2 Based Immunotherapy Prevents Late Events in High-Risk Neuroblastoma Patients over 18 Months at Diagnosis. Cancers, 13(19), 4941. https://doi.org/10.3390/cancers13194941